Viral Clearance Market Worth $724.5 million – Emerging Industry and Increasing Pharmaceutical Outsourcing

PUNE, India, 2021-Feb-22 — /EPR Network/ —

According to the new market research report “Viral Clearance Market by Application (Recombinant Proteins, Blood, Vaccines), End User (Pharmaceutical & Biotechnology Companies, CROs), Method (Viral Removal (Chromatography, Nanofiltration), Viral Inactivation (Low pH)) – Global Forecast” published by MarketsandMarkets™.

Revenue Growth Opportunities:  The Global Viral Clearance Market is expected to reach USD 724.5 million by 2023 from an estimated USD 271.2 million in 2018, at a CAGR of 21.7% during the forecast period.

Major Growth Boosting Factors:

# Growth in the Pharmaceutical and Biotechnology Industries
# Increasing Number of Drug Launches
# Favorable R&D Investment Scenario
# Possibility of Cell Culture Contamination
# Advancements in Nanofiltration Technology

Objectives of the Study;

# To define, measure, and describe the global viral clearance market by application, method, end user, and region

# To provide detailed information about the major factors influencing market growth (drivers, restraints, challenges, and opportunities)

# To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market

# To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players

Request Research Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=62681197

On the basis of application,

Segmented into four categories recombinant proteins, blood and blood products, vaccines, and other applications. In 2018, the recombinant proteins segment is expected to account for the largest share of the viral clearance market owing to the high potential of recombinant proteins to treat various diseases, fewer side effects, and shorter development time as compared to small molecules. Furthermore, the regulatory requirement to demonstrate the capacity of the purification process to effectively clear infectious viruses during the manufacturing of recombinant proteins is also expected to support the growth of this market segment during the forecast period.

By end user,

Segmented into pharmaceutical & biotechnology companies, CROs, academic research institutes, and other end users. In 2018, the pharmaceutical & biotechnology companies segment is expected to account for the largest share of the global market. The large share of this segment can be attributed to the rapid expansion of the biopharmaceutical industry, growth in the number of research activities in life sciences, increasing R&D investments in drug development, and increasing number of drug launches.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=62681197

Geographical Scenario: The North American region is expected to account for the largest share of the market in 2018. The viral clearance market in the region is driven by the presence of national institutes supporting biotechnology and life science research, growth in the pharmaceuticals industry, and the increasing number of drug approvals. The rising prevalence of diseases, growing production of monoclonal antibodies, and government support for the development of drugs are some of the key factors driving the market in the US. In Canada, increasing pharmaceutical production is expected to boost the growth of the market.

However, Asia Pacific is expected to witness the highest growth during the forecast period, owing to increase in generics development and manufacturing, surge in funding for medical research and the presence of a large number of CROs to provide preclinical and clinical research services in China, government initiatives to boost the use of generic drugs, increasing aging population in Japan, rise in pharmaceutical R&D expenditures in India, and the growing pharmaceutical manufacturing in Singapore and Malaysia.

Global Leaders:

The key players in the global viral clearance market are Wuxi Biologics (Cayman) (China), Merck KGaA (Germany), Charles River Laboratories International Inc. (US), and Texcell Inc. (France). These companies together accounted for 70.0% of the global market. Other players together accounted for 30.0% of the market. These include Kedrion (Italy), Vironova Biosafety (Sweden), Clean Cells (France), BSL BIOSERVICE Scientific Laboratories Munich GmbH (Germany), and ViruSure GmbH (Austria).